Investigation of TGFB1 −1347C>T variant as a biomarker after allogeneic hematopoietic stem cell transplantation
Bone Marrow Transplantation, Published online: 16 September 2019; doi:10.1038/s41409-019-0656-4Investigation of TGFB1 −1347C>T variant as a biomarker after allogeneic hematopoietic stem cell transplantation
ConclusionWe confirmed that myeloablative Bu/Flu conditioning has comparable clinical and QOL outcomes to Bu/Cy.
A new study from the University of California Santa Cruz gave mice a dose of Viagra followed by an injection of another drug. It helped stem cells detach from bone marrow in just two hours.
Bone Marrow Transplantation, Published online: 04 October 2019; doi:10.1038/s41409-019-0706-yCorrection: Complete remission of seronegative rheumatoid arthritis following haplo-identical stem cell transplantation for peripheral T-cell lymphoma
Abstract Haploidentical hematopoietic stem cell transplantation has been growing steadily since 2012. The SFGM-TC has twice published guidelines concerning T-cell repleted haploidentical grafts with high dose cyclophosphamide post-transplantation. The 2013 workshop recommended using the non-myeloablative Baltimore protocol with bone marrow and developed prospective protocols to evaluate these transplantations. The 2015 workshop reported improved results of reduced conditioning regimens in Hodgkin's lymphoma and intensive conditioning in myeloid hemopathies, and a similar outcome with 10/10 HLA matched donor with t...
ConclusionsFor patients in CR1, the impact of FLT3ITD is markedly modified by NPM1 status. The post-transplant outcome remains poor for patients of FLT3ITDmutNPM1wt and highlights the need for a novel approach (such as maintenance FLT3ITD inhibitor after transplant). For patients after CR1, the post-transplant outcome is very poor for patients of FLT3ITDmut and is independent of NPM1 status.Legal entity responsible for the studyThe author.FundingHas not received any funding.DisclosureThe author has declared no conflicts of interest.
Bone Marrow Transplantation, Published online: 30 September 2019; doi:10.1038/s41409-019-0701-3Changing epidemiology of bloodstream infection in a 25-years hematopoietic stem cell transplant program: current challenges and pitfalls on empiric antibiotic treatment impacting outcomes
Bone Marrow Transplantation, Published online: 27 September 2019; doi:10.1038/s41409-019-0702-2Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party
Bone Marrow Transplantation, Published online: 27 September 2019; doi:10.1038/s41409-019-0699-6Pre-emptive rituximab treatment for Epstein–Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes
In conclusion, various influencing factors must be taken into consideration during the cryopreservation of HSCs, especially for poor mobilizing patients with a low number of collected hematopoietic stem cells. PMID: 31563591 [PubMed - as supplied by publisher]
Bone Marrow Transplantation, Published online: 26 September 2019; doi:10.1038/s41409-019-0684-0Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)